AFG3L1P: A Drug Target / Disease Biomarker (G172)

Target Name: AFG3L1P

NCBI ID: G172

AFG3L1P

AFG3L1P: A Drug Target / Disease Biomarker

AFG3L1P, also known as ALDH1L1, is a gene that encodes a protein known as the alpha-glucosidase 3-like 1 (AFG3L1). This gene is located on chromosome 19 and has been identified as a potential drug target or biomarker for several diseases.

The alpha-glucosidase 3-like 1 (AFG3L1) is a protein that is involved in the breakdown of certain types of sugar molecules, known as glucose. There are several different forms of this protein, each with a different function. The most abundant form of AFG3L1 is the alpha-glucosidase alpha-glucosidase 3-like 1 (AFG3L1), which is responsible for breaking down the sugar molecules in the cell's cytoplasm.

AFG3L1P has been shown to be involved in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In addition, research has also suggested that AFG3L1P may have potential as a drug target for treating these diseases.

One of the potential reasons why AFG3L1P has been identified as a drug target is because it is involved in the production of certain types of cancer cells. Many studies have shown that cancer cells are able to produce large amounts of AFG3L1, and that this production is associated with the development and progression of certain types of cancer.

Another potential reason why AFG3L1P has been identified as a drug target is because it is involved in the production of certain neurodegenerative diseases. Many of these diseases, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells and the development of certain symptoms.

It is thought that the AFG3L1 protein may be involved in the production of these diseases because it is involved in the breakdown of certain types of sugar molecules that are important for the healthy functioning of the brain cells. The breakdown of these sugar molecules may contribute to the progressive loss of brain cells and the development of certain symptoms in these diseases.

In addition to its potential role in the production of certain types of cancer and neurodegenerative diseases, AFG3L1P has also been shown to be involved in the development and progression of autoimmune disorders. Many of these disorders, such as rheumatoid arthritis and multiple sclerosis, are characterized by the immune system attacking the body's own tissues.

It is thought that the AFG3L1 protein may be involved in the development and progression of these disorders because it is involved in the production of certain immune cells that play a key role in the immune response. The production of these cells may contribute to the immune system's attack on the body's own tissues, leading to the development and progression of these autoimmune disorders.

Overall, AFG3L1P is a protein that has been shown to be involved in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, it is a potential drug target or biomarker for these diseases and could be used for the development of new treatments.

Protein Name: AFG3 Like Matrix AAA Peptidase Subunit 1, Pseudogene

The "AFG3L1P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AFG3L1P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets